Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

By P. Paik, M. Arcila, Michael Fara, C. Sima, Vincent A. Miller, M. Kris, Marc Ladanyi, Gregory Riely. Journal of Clinical Oncology, 2011

679 citations recorded by the source corpus.

Subfields: Molecular Biology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/f09788c6330bdac1ea0591aab0ce705f50770b56

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. C. Zappa
2. Shaker A. Mousa

Citations in the corpus

• MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. (2016, neutral): “5 (59-84) 61 (30-93) 65 (42-93) Sex Male 9 (32) 30 (30) 62 (37) Female 19 (68) 69 (70) 107 (63) Smoking history, pack-years* Never-smoker 10 (36) 57 (58) 6 (4) # 10 3 (11) 10 (10) 11 (7) .”
• Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs (2014, neutral): “EGFR (sensitizing)e 175 (17) [15-20] 122 (17) [14-20] 146 (83)”
• Non-small cell lung cancer: current treatment and future advances. (2016, background): “com present in 18 (3%), of which the BRAF mutations identified were V600E (50%), G469A (39%) and D594G (11%) (69).”
• ERK/MAPK signalling pathway and tumorigenesis (2020, background): “Among the three subtypes, B-Raf has the highest mutation rate, which is 90% in melanoma (Table I) (51-73).”